Abstract:Breast cancer is the most common malignant tumors among women in the worldwide. The status of estrogen receptor in breast cancer is usually associated with prognosis and response to hormonal therapy. estrogen receptor status varies among breast cancers, with one third of the disease showing estrogen receptor negative. Absence of estrogen receptor is known to be associated with poor differentiation of tumor cells, resistance to hormonal therapy, and poor clinical outcome; thus, a better understanding of the causes and mechanisms underlying the loss or reduction of estrogen receptor in breast cancer may help identify novel strategy for treating breast cancer. We recently found that the expression of ubiquitin C terminal hydrolaseL1 (UCHL1), an enzyme that uniquely possesses both ubiquitin hydrolase and ligase activity, is conversely related with estrogen receptor status in breast cancer. UCHL1 is overexpressed in estrogen receptor (-) breast cancer cell lines and tumor samples, but is barely detectable in estrogen receptor (+) breast cancer cell lines and tumor samples. Overexpression of UCHL1 in estrogen receptor (+) cells resulted in a remarkable reduction of estrogen receptor mRNA and protein; however, UCHL1 inhibitor or UCHL1 siRNA upregulated the protein and mRNA levels of estrogen receptor in estrogen receptor (-) cells. We further demonstrated that the regulatory effect of UCHL1 on estrogen receptor resulted from this deubiquitylase-mediated stability of EGFR, which promotes the transcription of estrogen receptor. Inhibition of UCHL1 could significantly enhance the sensitivity of estrogen receptor (-) breast cancer cells to tamoxifen, the most commonly used anti estrogen agent in the treatment of this disease. These data demonstrated that UCHL1 may be a potential molecule target to sensitize hormone resistant human breast cancers to anti estrogen agent. Our findings not only provided a basis for new approaches to upregulating estrogen receptor level, but also present a new rationale strategy for developing more effective therapies for estrogen receptor negative breast cancer, and a new pharmacologic target for drug development.

UHRF1 Modulates Breast Cancer Cell Growth Via Estrogen Signaling

Exogenous expression of UHRF1 promotes proliferation and metastasis of breast cancer cells.

UHRF1 knockdown induces cell cycle arrest and apoptosis in breast cancer cells through the ZBTB16/ANXA7/Cyclin B1 axis

Evaluation of Expression of UHRF1 and Its Prognostic and Clinicopathological Value in Human Malignancies: A Systematic Review and Meta-analysis

UHRF1 Promotes Breast Cancer Progression by Suppressing KLF17 Expression by Hypermethylating Its Promoter.

The ubiquitin ligase RNF181 stabilizes ERα and modulates breast cancer progression

Upregulation Of Uhrf1 Promotes Renal Cancer Metastasis And Poor Prognosis

Overexpression of UHRF1 and its potential role in the development of invasive ductal breast cancer validated by integrative bioinformatics and immunohistochemistry analyses

UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer

UHRF1 plays an oncogenic role in small cell lung cancer

Inhibition of UCHL1 Enhances the Sensitivity of Estrogen Receptor Negative Breast Cancer Cells to Endocrine Therapy

UHRF1 Knockdown Attenuates Cell Growth, Migration, and Invasion in Cutaneous Squamous Cell Carcinoma

Modification of ERα by UFM1 Increases Its Stability and Transactivity for Breast Cancer Development

Diagnostic and prognostic value of plasma and tissue ubiquitin-like, containing PHD and RING finger domains 1 in breast cancer patients.

Signalling pathways in UHRF1-dependent regulation of tumor suppressor genes in cancer

UHRF1 Promotes Proliferation of Gastric Cancer Via Mediating Tumor Suppressor Gene Hypermethylation.

UHRF2 promotes Hepatocellular Carcinoma Progression by Upregulating ErbB3/Ras/Raf Signaling Pathway

Identification of Differentially Expressed Tumour-Related Genes Regulated by UHRF1-driven DNA Methylation

Roles of post-translational modifications of UHRF1 in cancer

Regulation of Estrogen Signaling and Breast Cancer Proliferation by an Ubiquitin Ligase TRIM56

UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer.